Premium
Malignant melanoma in early Parkinson's disease: The DATATOP trial
Author(s) -
Constantinescu Radu,
Romer Megan,
Kieburtz Karl
Publication year - 2007
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.21273
Subject(s) - medicine , melanoma , incidence (geometry) , context (archaeology) , epidemiology , cohort , population , confidence interval , disease , levodopa , parkinson's disease , oncology , standardized mortality ratio , dermatology , paleontology , physics , environmental health , cancer research , optics , biology
The available epidemiological data on the incidence of malignant melanoma in Parkinson's disease are contradictory. The role of levodopa therapy in this context has been debated. We identified all known cases of malignant melanoma (N = 5) in the DATATOP clinical trial cohort and compared that to published expected values (N = 1.5) for a standard healthy population. The standardized event ratio was 3.3 (95% confidence interval, 1.1–7.8), indicating that incidence of malignant melanoma was higher than expected. We found no association between levodopa therapy and the incidence of melanoma. © 2007 Movement Disorder Society